| Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation L Shan, K Deng, NS Shroff, CM Durand, SA Rabi, HC Yang, H Zhang, ... Immunity 36 (3), 491-501, 2012 | 855 | 2012 |
| Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations K Deng, M Pertea, A Rongvaux, L Wang, CM Durand, G Ghiaur, J Lai, ... Nature 517 (7534), 381-385, 2015 | 571 | 2015 |
| New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo CK Bullen, GM Laird, CM Durand, JD Siliciano, RF Siliciano Nature medicine 20 (4), 425-429, 2014 | 553 | 2014 |
| Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating … JR Bailey, AR Sedaghat, T Kieffer, T Brennan, PK Lee, M Wind-Rotolo, ... Journal of virology 80 (13), 6441-6457, 2006 | 507 | 2006 |
| Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations GM Laird, CK Bullen, DIS Rosenbloom, AR Martin, AL Hill, CM Durand, ... The Journal of clinical investigation 125 (5), 1901-1912, 2015 | 415 | 2015 |
| Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus–infected donors to noninfected recipients: an open-label nonrandomized trial CM Durand, MG Bowring, DM Brown, MA Chattergoon, G Massaccesi, ... Annals of internal medicine 168 (8), 533-540, 2018 | 295 | 2018 |
| Early impact of COVID‐19 on transplant center practices and policies in the United States BJ Boyarsky, T Po‐Yu Chiang, WA Werbel, CM Durand, RK Avery, ... american Journal of Transplantation 20 (7), 1809-1818, 2020 | 275 | 2020 |
| The drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study CM Durand, MG Bowring, AG Thomas, LM Kucirka, AB Massie, ... Annals of internal medicine 168 (10), 702-711, 2018 | 204 | 2018 |
| Transcriptional reprogramming during effector-to-memory transition renders CD4+ T cells permissive for latent HIV-1 infection L Shan, K Deng, H Gao, S Xing, AA Capoferri, CM Durand, SA Rabi, ... Immunity 47 (4), 766-775. e3, 2017 | 199 | 2017 |
| The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases JA Kanakry, AM Hegde, CM Durand, AB Massie, AE Greer, RF Ambinder, ... Blood, The Journal of the American Society of Hematology 127 (16), 2007-2017, 2016 | 193 | 2016 |
| Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance SA Rabi, GM Laird, CM Durand, S Laskey, L Shan, JR Bailey, S Chioma, ... The Journal of clinical investigation 123 (9), 3848-3860, 2013 | 182 | 2013 |
| Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C RJ Fontana, EA Hughes, M Bifano, H Appelman, D Dimitrova, R Hindes, ... American Journal of Transplantation 13 (6), 1601-1605, 2013 | 159 | 2013 |
| Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10‐year, single‐center experience D Neofytos, S Treadway, D Ostrander, CD Alonso, KL Dierberg, ... Transplant Infectious Disease 15 (3), 233-242, 2013 | 146 | 2013 |
| HIV-1 DNA Is Detected in Bone Marrow Populations Containing CD4+ T Cells but Is not Found in Purified CD34+ Hematopoietic Progenitor Cells in Most Patients … CM Durand, G Ghiaur, JD Siliciano, SA Rabi, EE Eisele, M Salgado, ... Journal of Infectious Diseases 205 (6), 1014-1018, 2012 | 135 | 2012 |
| A national study of outcomes among HIV-infected kidney transplant recipients JE Locke, S Mehta, RD Reed, P MacLennan, A Massie, A Nellore, ... Journal of the American Society of Nephrology 26 (9), 2222-2229, 2015 | 134 | 2015 |
| Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation V Leroy, J Dumortier, A Coilly, M Sebagh, C Fougerou-Leurent, ... Clinical Gastroenterology and Hepatology 13 (11), 1993-2001. e2, 2015 | 133 | 2015 |
| Developing strategies for HIV-1 eradication CM Durand, JN Blankson, RF Siliciano Trends in immunology 33 (11), 554-562, 2012 | 119 | 2012 |
| Changes in utilization and discard of hepatitis C–infected donor livers in the recent era MG Bowring, LM Kucirka, AB Massie, X Luo, A Cameron, M Sulkowski, ... American Journal of Transplantation 17 (2), 519-527, 2017 | 113 | 2017 |
| Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late AM Pellicelli, M Montalbano, R Lionetti, C Durand, P Ferenci, G D’Offizi, ... Digestive and Liver Disease 46 (10), 923-927, 2014 | 102 | 2014 |
| Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection RJ Fontana, RS Brown Jr, A Moreno‐Zamora, M Prieto, S Joshi, ... Liver Transplantation 22 (4), 446-458, 2016 | 93 | 2016 |
